DNA vaccines with single-chain Fv fused to fragment C of tetanus toxin induce protective immunity against lymphoma and myeloma
- PMID: 9809552
- DOI: 10.1038/3266
DNA vaccines with single-chain Fv fused to fragment C of tetanus toxin induce protective immunity against lymphoma and myeloma
Abstract
Vaccination with idiotypic protein protects against B-cell lymphoma, mainly through anti-idiotypic antibody. For use in patients, DNA vaccines containing single-chain Fv derived from tumor provide a convenient alternative vaccine delivery system. However, single-chain Fv sequence alone induces low anti-idiotypic response and poor protection against lymphoma. Fusion of the gene encoding fragment C of tetanus toxin to single-chain Fv substantially promotes the anti-idiotypic response and induces strong protection against B-cell lymphoma. The same fusion design also induces protective immunity against a surface Ig-negative myeloma. These findings indicate that fusion to a pathogen sequence allows a tumor antigen to engage diverse immune mechanisms that suppress growth. This fusion design has the added advantage of overcoming potential tolerance to tumor that may exist in patients.
Comment in
-
Giving DNA vaccines a helping hand.Nat Med. 1998 Nov;4(11):1239-40. doi: 10.1038/3217. Nat Med. 1998. PMID: 9809542 No abstract available.
Similar articles
-
DNA vaccines against lymphoma: promotion of anti-idiotypic antibody responses induced by single chain Fv genes by fusion to tetanus toxin fragment C.J Immunol. 1997 Aug 15;159(4):1885-92. J Immunol. 1997. PMID: 9257853
-
Plant viral genes in DNA idiotypic vaccines activate linked CD4+ T-cell mediated immunity against B-cell malignancies.Nat Biotechnol. 2001 Aug;19(8):760-4. doi: 10.1038/90816. Nat Biotechnol. 2001. PMID: 11479570
-
Vaccination with DNA encoding a single-chain TCR fusion protein induces anticlonotypic immunity and protects against T-cell lymphoma.Cancer Res. 2002 Mar 15;62(6):1757-60. Cancer Res. 2002. PMID: 11912151
-
DNA fusion gene vaccines against cancer: from the laboratory to the clinic.Immunol Rev. 2004 Jun;199:156-80. doi: 10.1111/j.0105-2896.2004.00145.x. Immunol Rev. 2004. PMID: 15233733 Review.
-
Idiotypic vaccination for B-cell malignancies as a model for therapeutic cancer vaccines: from prototype protein to second generation vaccines.Haematologica. 2002 Sep;87(9):989-1001. Haematologica. 2002. PMID: 12217812 Review.
Cited by
-
Therapeutic vaccine for lymphoma.Yonsei Med J. 2007 Feb 28;48(1):1-10. doi: 10.3349/ymj.2007.48.1.1. Yonsei Med J. 2007. PMID: 17326239 Free PMC article. Review.
-
Immunotherapy for lymphomas.Int J Hematol. 2003 Jun;77(5):444-55. doi: 10.1007/BF02986612. Int J Hematol. 2003. PMID: 12841382 Review.
-
scFv6.C4 DNA vaccine with fragment C of Tetanus toxin increases protective immunity against CEA-expressing tumor.Gene Ther. 2019 Nov;26(10-11):441-454. doi: 10.1038/s41434-019-0062-y. Epub 2019 Feb 15. Gene Ther. 2019. PMID: 30770895
-
Therapeutic vaccines for non-Hodgkin B-cell lymphoma.Clin Transl Oncol. 2008 Sep;10(9):543-51. doi: 10.1007/s12094-008-0249-4. Clin Transl Oncol. 2008. PMID: 18796371 Review.
-
Generation of High-Specificity Antibodies against Membrane Proteins Using DNA-Gold Micronanoplexes for Gene Gun Immunization.Curr Protoc Protein Sci. 2018 Feb 21;91:29.20.1-29.20.22. doi: 10.1002/cpps.50. Curr Protoc Protein Sci. 2018. PMID: 29516482 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
